Cambridge Enterprise, the tech transfer office of Cambridge University, the institution’s Enterprise Fund IV and Cambridge Innovation Capital have supported a £720,000 ($935,000) funding round for PervasID, a spinout of Cambridge University. A private investor also took part in the round. PervasID has created technology to passively detect and read standard, off-the-shelf UHF RFID tags over areas of up to 400 square meters.
Cambridge Enterprise has also licensed a technology called Predict, which helps doctors choose the best course forward following breast cancer surgery, to clinical decision support app provider OncoAssist, according to Business Weekly. Predict is based on research conducted at the Breast Unit at Cambridge University Hospitals NHS Trust, the university’s Department of Oncology and the NHS Eastern Cancer Registry and Information Centre.
Medherant, a drug delivery patch spinout of Warwick University, has attracted £1.5m in funding from commercialisation firm Mercia Technologies and unnamed backers. Mercia injected £650,000. The money will advance pre-clinical trials of the company’s Tepi Patch, a transdermal drug delivery patch that hopes to provide up to 24 hours of pain relief.
Imperial Innovations, the commercialisation firm set up by Imperial College London, has led a £1.6m seed round for ThisWay, a company based on research at Cambridge University and University College London that is using machine learning to match jobseekers with opportunities. The round was supported by GPHR Ventures, the investment arm of recruitment firm Grupa Pracuj, and Jetstream Ventures. ThisWay was incubated by Cambridge’s IdeaSpace program.
